| Sanofi-Aventis (Suisse) SA - Revaxis, suspension injectable | | 00646 | | 01 | | Revaxis | | suspension injectable | | J07CA01 | | Diphtherie-Poliomyelitis-Tetanus | | 10.08.2000 | | |
| | Composition | | toxoidum tetani min. 20 U.I., toxoidum diphtheriae min. 2 U.I., virus poliomyelitis typus 1 inactivatus 29 U., virus poliomyelitis typus 2 inactivatus 7 U., virus poliomyelitis typus 3 inactivatus 26 U., aluminium 0.35 mg ut aluminii hydroxidum hydricum ad adsorptionem, formaldehydum, medium 199 cum phenylalaninum 12.5 µg, phenoxyethanolum, ethanolum anhydricum 2 mg, acidum hydrochloridum, natrii hydroxidum, acidum aceticum, aqua ad iniectabile, ad suspensionem pro 0.5 ml corresp., kalium 0.12 mg et natrium 1.6 mg, residui: neomycinum, streptomycinum, polymyxinum B. | | Packungsbestandteile | | Suspension injectable | | | | | | | | Principe actif | Concentr. |
|---|
| Toxoidum Diphtheriae | 2U.I. / 0.5ml | | Toxoidum Tetani | 20U.I. / 0.5ml |
| | BAG: Principe actif | Concentr. |
|---|
| Toxoidum Diphtheriae | 2 UI | | Toxoidum Tetani | 20 UI | | Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) | 62 U |
| | | | Agents auxilliaires | Concentr. |
|---|
| Acide Acétique | | | Acidum Hydrochloridum | | | Alumine | 0.35mg / 0.5ml | | Cum Phenylalaninum | 12.5µg / 0.5ml | | Ethanol Anhydrate | 2mg / 0.5ml | | Formaldehydum | | | Inactivatus | 26U. / 0.5ml | | Medium | 199 | | Sodium Hydroxide | | | Phénoxyéthanol | | | Virus Poliomyelitis Typus | 3 |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | 11.86 | 29.30 | B | LS | Non | | 004 | 10 | DDP | DDP | B | | Non |
|
|
